SG11201811258UA - Process for the production of a dna vaccine for cancer immunotherapy - Google Patents
Process for the production of a dna vaccine for cancer immunotherapyInfo
- Publication number
- SG11201811258UA SG11201811258UA SG11201811258UA SG11201811258UA SG11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA SG 11201811258U A SG11201811258U A SG 11201811258UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dna vaccine
- pct
- transformed cell
- cancer immunotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811258UA true SG11201811258UA (en) | 2019-01-30 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811258UA SG11201811258UA (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (https=) |
| EP (1) | EP3484503A1 (https=) |
| JP (2) | JP7098599B2 (https=) |
| KR (3) | KR20190027834A (https=) |
| CN (1) | CN109475614A (https=) |
| AU (1) | AU2017295004B2 (https=) |
| BR (1) | BR112019000657A2 (https=) |
| CA (1) | CA3028549A1 (https=) |
| IL (1) | IL263568A (https=) |
| MX (1) | MX2019000415A (https=) |
| RU (1) | RU2019100079A (https=) |
| SG (1) | SG11201811258UA (https=) |
| WO (1) | WO2018011289A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018149982A1 (en) * | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| EP3652318A1 (en) | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| JP7598315B2 (ja) * | 2018-09-05 | 2024-12-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| US20230121528A1 (en) | 2020-01-13 | 2023-04-20 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| WO2024005122A1 (ja) * | 2022-06-30 | 2024-01-04 | 株式会社島津製作所 | 微生物の分析の準備方法、および、微生物の分析方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3892295T3 (pl) * | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| CA2853656C (en) * | 2011-12-22 | 2020-12-29 | Vaximm Ag | Method of producing high yield attenuated salmonella strains |
| JP6325534B2 (ja) | 2012-07-05 | 2018-05-16 | バクシム アクチェンゲゼルシャフト | 膵臓癌患者用ｄｎａワクチン |
| MX364922B (es) * | 2013-04-25 | 2019-05-14 | Vaximm Ag | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. |
| SI3082850T1 (sl) * | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | DNA cepivo, ki cilja MSLN za imunoterapijo raka |
| KR20230076867A (ko) * | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
-
2017
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 KR KR1020267008900A patent/KR20260047288A/ko active Pending
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017295004B2 (en) | 2020-08-13 |
| EP3484503A1 (en) | 2019-05-22 |
| AU2017295004A1 (en) | 2019-01-03 |
| RU2019100079A (ru) | 2020-08-13 |
| US11590215B2 (en) | 2023-02-28 |
| KR20190027834A (ko) | 2019-03-15 |
| WO2018011289A1 (en) | 2018-01-18 |
| JP2022097591A (ja) | 2022-06-30 |
| JP2019521154A (ja) | 2019-07-25 |
| BR112019000657A2 (pt) | 2019-04-24 |
| JP7098599B2 (ja) | 2022-07-11 |
| US10821163B2 (en) | 2020-11-03 |
| US20190183996A1 (en) | 2019-06-20 |
| CN109475614A (zh) | 2019-03-15 |
| IL263568A (en) | 2019-01-31 |
| KR20230079514A (ko) | 2023-06-07 |
| CA3028549A1 (en) | 2018-01-18 |
| US20220072112A1 (en) | 2022-03-10 |
| MX2019000415A (es) | 2019-03-28 |
| KR20260047288A (ko) | 2026-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811258UA (en) | Process for the production of a dna vaccine for cancer immunotherapy | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201810149VA (en) | Anti hla-g specific antibodies | |
| SG11201909154SA (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201808476SA (en) | Recycling of polymer matrix composite | |
| SG11201908088RA (en) | Antibodies against pd-l1 | |
| SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201811015RA (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201906313SA (en) | A polypeptide linker for preparing multispecific antibodies | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201804888WA (en) | Velocity model update with an inversion gradient | |
| SG11201807949WA (en) | Engineered immunoglobulins with altered fcrn binding |